Which biotech startups are basing their technology on the CRISPR/CAS system?
The global markets for CRISPR-Cas9 genome editing were estimated at $1.22 billion in 2017 and it is expected to reach $5.3 billion by 2025 growing at a CAGR of 20.19 percent.
CRISPR Landscape is already witnessing germination of second-generation startups which are swiftly advancing this technology to pioneer breakthrough applications. Featured below are a few of the novel gene editing companies presently active:
- Mammoth Biosciences
- Agenovir Corporation
- eGenesis
- Plantedit
- NTrans Technologies
- Beam Therapeutics
Large biotech companies like Millipore Sigma (earlier Sigma Aldrich), Thermo Fisher Scientific, Toolgen, Genecopeia, Horizon Discovery, and Agilent Technologies and pharmaceuticals like Novartis, Vertex, Bayer AG, AstraZeneca, Evolva, Juno Therapeutics, and GE Healthcare have skin in the CRISPR game exploring novel techniques to evolve their drug discovery and development processes. They are forming strategic alliances with crucial CRISPR technology companies like Crispr Therapeutics, Editas Medicine, Caribou Biosciences and Intellia Therapeutics to devise gene-based therapies for various genetic diseases.
List of companies active in CRISPR-Cas9 genome editing market:
- Addgene
- Agilent Technologies Inc.
- Applied Biological Materials Inc
- ATUM (formerly DNA2.0)
- Caribou Biosciences
- Casebia Therapeutics
- Crispr Therapeutics
- Editas Medicine
- Genecopeia
- Genscript
- Horizon Discovery (Dharmacon)
- Intellia Therapeutics
- New England Biolabs
- Origene Technologies Inc.
- Sigma Aldrich (acquired by Merck)
- System Biosciences
- Takara Bio USA, Inc. (formerly Clontech Laboratories)
- Thermo Fisher Scientific
- Toolgen Inc.
- Transposagen Biopharmaceutical
View the complete: CRISPR Cas9 Tools Market and Patent Landscape Report here
No comments:
Post a Comment